Ä¢¹½ÊÓƵAPP

Vesalius is taking a novel approach to create drugs to treat the common diseases that represent the vast majority of disease burden in industrialized societies. Vesalius’s Physio-Logic platform applies proprietary artificial intelligence and big data techniques to analyze clinical and genetic information from large groups of patients. The insights that emerge from this approach make it possible to identify groups of clinically similar people and novel proteins that can be targeted to treat them. It validates these insights in proprietary human-based model systems. Physio-Logic is making it possible to streamline drug discovery, accelerate clinical trials, and increase the probability of success of these trials for the diseases that matter most.